- 5-Amino-1MQ (5A1MQ)
Small molecule NNMT inhibitor that may enhance fat metabolism and improve metabolic health through epigenetic mechanisms.
- Adipotide (FTPP) (FTPP)
Adipotide (also known as FTPP or prohibitin-targeting peptide) is a peptidomimetic that selectively targets and destroys blood vessels supplying white adipose t
- AOD-9604 (AOD)
Fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without the growth-promoting effects of HGH.
- BNP (Brain Natriuretic Peptide) (BNP)
Cardiac hormone that regulates fluid balance and blood pressure. Nesiritide is the synthetic form used in heart failure.
- Dulaglutide (DULA)
Dulaglutide (marketed as Trulicity) is an FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes. It consists of a GLP-1 analog fused to a modified
- Exenatide (EXEN)
Exenatide (marketed as Byetta and Bydureon) is a GLP-1 receptor agonist originally derived from the saliva of the Gila monster lizard. It was the first GLP-1-ba
- GHRP-6 (Cardiac) (GHRP6C)
Beyond GH release, GHRP-6 has demonstrated independent cardioprotective effects in ischemia research.
- Liraglutide (LIRA)
Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It shares 97% homology with na
- MOTS-c (MOTSC)
Mitochondria-derived peptide that regulates metabolic homeostasis and has shown effects on insulin sensitivity and fat metabolism.
- Retatrutide (RETA)
Triple agonist targeting GIP, GLP-1, and glucagon receptors. Showing unprecedented weight loss in clinical trials.
- Semaglutide (SEMA)
GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy.
- Tirzepatide (TIRZ)
Dual GIP/GLP-1 receptor agonist showing superior weight loss compared to GLP-1 agonists alone. Brand names include Mounjaro and Zepbound.